Delinia is a biotechnology company that is developing novel therapeutics for treating autoimmune diseases. The lead novel therapeutics of Delinia provides treatment to potentiate and expand regulatory T cells and immune cells that are important to maintaining self-tolerance and immune system homeostasis. The treatment works with the potential to selectively treat immune disorders without suppressing a patient’s immune system.
Delinia is creating novel therapeutics that rebalance the immune system for treating serious and life-threatening autoimmune diseases. Delinia has a novel protein therapeutic platform that is built on technology which was created by co-founder and Chief Scientific Officer, Jeffrey Greve PhD.
Its platform targets, activates, and augments the levels of Tregs, a cell type that exists naturally in the body and whose function is to regulate the inflammatory response of other cells.
Delinia has been acquired by Celgene Corporation.
